Scholarlink

<p>Gliomas are aggressive primary brain tumors with poor treatment outcomes due to their infiltrative nature and therapy resistance. To address this, we developed a targeted nanoplatform based on compound 1 (1), a bioactive molecule extracted from <i>Momordica charantia</i> (<i>M. charantia</i>), functionalized with 3-aminopropyltrimethoxysilane (APTMS) and D-glucosamine (GlcN) to yield GlcN-1-APTMS@CP1, and further loaded with quercetin (Qu) to form GlcN-1-APTMS@CP1@Quercetin. This system exhibited efficient drug loading (pore size reduced from 416.65&#xa0;μm to 320.68&#xa0;μm), pH/redox-responsive release, and strong fluorescence at 460&#xa0;nm. It showed high selectivity for Fe<sup>3</sup>⁺ and glioma biomarkers, particularly Bcl-2 (K = 4.04 × 10<sup>4</sup>&#xa0;M⁻<sup>1</sup>, R<sup>2</sup> = 0.9941), with robust stability and anti-interference performance. In vitro, the platform effectively triggered glioma cell apoptosis via the Bcl-2/Bax pathway, highlighting its potential as a plant-derived, quercetin-loaded nanomedicine for glioma therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Polysaccharide–Silica Fluorescent Polymer Carrier for Selective Sensing and Glioblastoma Multiforme Therapy

  • 期刊论文

  • 发表日期：

    2025年10月30日

查看全文
  • Haitao Tang,
  • Tianyao Wang,
  • Zhonghua Lv,
  • Jinsheng Xiong

摘要

Gliomas are aggressive primary brain tumors with poor treatment outcomes due to their infiltrative nature and therapy resistance. To address this, we developed a targeted nanoplatform based on compound 1 (1), a bioactive molecule extracted from Momordica charantia (M. charantia), functionalized with 3-aminopropyltrimethoxysilane (APTMS) and D-glucosamine (GlcN) to yield GlcN-1-APTMS@CP1, and further loaded with quercetin (Qu) to form GlcN-1-APTMS@CP1@Quercetin. This system exhibited efficient drug loading (pore size reduced from 416.65 μm to 320.68 μm), pH/redox-responsive release, and strong fluorescence at 460 nm. It showed high selectivity for Fe3⁺ and glioma biomarkers, particularly Bcl-2 (K = 4.04 × 104 M⁻1, R2 = 0.9941), with robust stability and anti-interference performance. In vitro, the platform effectively triggered glioma cell apoptosis via the Bcl-2/Bax pathway, highlighting its potential as a plant-derived, quercetin-loaded nanomedicine for glioma therapy.